MDGL FY2025 EPS Forecast Lifted by Cantor Fitzgerald

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Cantor Fitzgerald raised their FY2025 earnings per share estimates for Madrigal Pharmaceuticals in a report released on Wednesday, October 29th. Cantor Fitzgerald analyst P. Agrawal now expects that the biopharmaceutical company will post earnings of ($5.86) per share for the year, up from their prior estimate of ($6.98). The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. Cantor Fitzgerald also issued estimates for Madrigal Pharmaceuticals’ FY2026 earnings at $9.03 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.48) by $1.58. The business had revenue of $212.80 million during the quarter, compared to analysts’ expectations of $158.94 million. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%.The firm’s quarterly revenue was up 1357.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($7.10) earnings per share.

A number of other brokerages have also recently issued reports on MDGL. JMP Securities lifted their price objective on Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 20th. Piper Sandler lifted their price objective on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Truist Financial started coverage on Madrigal Pharmaceuticals in a report on Tuesday, October 14th. They issued a “buy” rating and a $580.00 target price for the company. HC Wainwright started coverage on Madrigal Pharmaceuticals in a report on Thursday, September 4th. They issued a “buy” rating and a $500.00 target price for the company. Finally, UBS Group reissued a “buy” rating and issued a $523.00 target price (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 12th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $532.70.

Madrigal Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ:MDGL opened at $418.90 on Friday. The stock has a fifty day simple moving average of $433.67 and a two-hundred day simple moving average of $352.25. The stock has a market capitalization of $9.30 billion, a price-to-earnings ratio of -32.60 and a beta of -1.02. Madrigal Pharmaceuticals has a 12-month low of $238.04 and a 12-month high of $463.63. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker acquired 59,901 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was bought at an average price of $385.16 per share, with a total value of $23,071,469.16. Following the completion of the acquisition, the director directly owned 1,947,968 shares of the company’s stock, valued at approximately $750,279,354.88. The trade was a 3.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kenneth Bate sold 10,000 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, August 15th. The stock was sold at an average price of $365.20, for a total value of $3,652,000.00. Following the completion of the sale, the director directly owned 2,627 shares of the company’s stock, valued at $959,380.40. The trade was a 79.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have purchased 165,683 shares of company stock valued at $61,921,142 and have sold 248,642 shares valued at $91,388,103. 21.50% of the stock is currently owned by insiders.

Institutional Trading of Madrigal Pharmaceuticals

Several hedge funds have recently bought and sold shares of MDGL. GAMMA Investing LLC grew its holdings in Madrigal Pharmaceuticals by 131.4% during the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 67 shares during the period. Cannon Global Investment Management LLC bought a new stake in Madrigal Pharmaceuticals during the first quarter valued at about $497,000. First Horizon Advisors Inc. grew its holdings in Madrigal Pharmaceuticals by 38.9% during the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 44 shares during the period. D.A. Davidson & CO. grew its holdings in Madrigal Pharmaceuticals by 203.9% during the first quarter. D.A. Davidson & CO. now owns 2,173 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 1,458 shares during the period. Finally, GF Fund Management CO. LTD. grew its holdings in Madrigal Pharmaceuticals by 21.8% during the first quarter. GF Fund Management CO. LTD. now owns 558 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 100 shares during the period. Institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.